Mirum Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Mirum Pharmaceuticals Inc 公司

Mirum Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于识别、收购、开发和商业化治疗衰弱性罕见病和孤儿病的疗法。该公司有三种药物：LIVMARLI（maralixibat）口服溶液（Livmarli）、Cholbam（胆酸）胶囊和 Chenodal（chenodiol）片剂。Livmarli 是一种口服、最低吸收的回肠胆汁酸转运蛋白 (IBAT) 抑制剂 (IBATi)，用于治疗美国和其他多个国家 Alagille 综合征 (ALGS) 患者的胆汁淤积性瘙痒以及美国进行性家族性肝内胆汁淤积 (PFIC) 患者的胆汁淤积性瘙痒。Cholbam 用于治疗因单一酶缺乏引起的胆汁酸合成障碍和过氧化物酶体疾病的辅助治疗。该公司还在推进其候选产品 volixibat，用于治疗患有胆汁淤积性肝病的成年患者。

Mirum Pharmaceuticals Inc简介



公司代码MIRM

公司名称Mirum Pharmaceuticals Inc

上市日期Jul 18, 2019

CEOMr. Christopher (Chris) Peetz

员工数量322

证券类型Ordinary Share

年结日Jul 18

公司地址989 East Hillsdale Boulevard, Suite 300

城市FOSTER CITY

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编94404

电话16506674085

网址https://mirumpharma.com/

公司代码MIRM

上市日期Jul 18, 2019

CEOMr. Christopher (Chris) Peetz

Mirum Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Christopher (Chris) Peetz

Chief Executive Officer, Co-Founder, Director

347.21K

--

Mr. Michael G. (Mike) Grey

Independent Chairman of the Board

280.16K

-26.84%

Ms. Lara Longpre

Chief Development Officer

104.41K

-0.80%

Dr. Pamela Vig, Ph.D.

Chief Scientific Officer, Head of Research

103.78K

--

Mr. Eric H. Bjerkholt

Chief Financial Officer

39.66K

+28.33%

Mr. Peter Radovich

President, Chief Operating Officer

18.67K

-30.74%

Ms. Laura A. Brege

Independent Director

15.70K

--

Mr. Patrick J. Heron

Independent Director

5.70K

--

Dr. Joanne Quan, M.D.

Chief Medical Officer

5.65K

--

Mr. Andrew Mckibben

Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Mr. Christopher (Chris) Peetz

Chief Executive Officer, Co-Founder, Director

347.21K

--

Mr. Michael G. (Mike) Grey

Independent Chairman of the Board

280.16K

-26.84%

Ms. Lara Longpre

Chief Development Officer

104.41K

-0.80%

Dr. Pamela Vig, Ph.D.

Chief Scientific Officer, Head of Research

103.78K

--

Mr. Eric H. Bjerkholt

Chief Financial Officer

39.66K

+28.33%

Mr. Peter Radovich

President, Chief Operating Officer

18.67K

-30.74%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

业务USD

名称

营收

占比

Livmarli

88.16M

68.99%

Bile Acid Medicines

39.63M

31.01%

License and other revenue

0.00

0.00%

暂无数据

业务

地区

业务USD

名称

营收

占比

Livmarli

88.16M

68.99%

Bile Acid Medicines

39.63M

31.01%

License and other revenue

0.00

0.00%

股东统计

更新时间: 10月31日周五

持股股东

股东类型

持股股东

占比

Frazier Life Sciences Management, L.P.

13.22%

Janus Henderson Investors

10.19%

BlackRock Institutional Trust Company, N.A.

6.04%

BVF Partners L.P.

5.37%

Eventide Asset Management, LLC

5.13%

其他

60.04%

持股股东

占比

Frazier Life Sciences Management, L.P.

13.22%

Janus Henderson Investors

10.19%

BlackRock Institutional Trust Company, N.A.

6.04%

BVF Partners L.P.

5.37%

Eventide Asset Management, LLC

5.13%

其他

60.04%

股东类型

持股股东

占比

Investment Advisor

34.70%

Investment Advisor/Hedge Fund

32.60%

Hedge Fund

21.58%

Private Equity

13.68%

Research Firm

4.26%

Venture Capital

2.92%

Individual Investor

1.84%

Sovereign Wealth Fund

0.99%

Pension Fund

0.69%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

468

57.20M

111.61%

-6.92M

2025Q2

458

58.36M

116.21%

-4.59M

2025Q1

454

57.59M

116.38%

-4.84M

2024Q4

425

56.60M

115.52%

-10.44M

2024Q3

408

56.58M

118.52%

-12.05M

2024Q2

398

57.22M

121.33%

-10.51M

2024Q1

391

57.27M

121.82%

-5.03M

2023Q4

376

54.05M

116.10%

-4.66M

2023Q3

337

55.34M

123.03%

+4.03M

2023Q2

315

43.67M

117.43%

-6.40M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Frazier Life Sciences Management, L.P.

6.80M

13.53%

--

Aug 18, 2025

Janus Henderson Investors

5.24M

10.42%

+154.32K

+3.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.10M

6.18%

+88.20K

+2.92%

Jun 30, 2025

BVF Partners L.P.

2.76M

5.5%

-35.18K

-1.26%

Jun 30, 2025

Eventide Asset Management, LLC

2.64M

5.25%

+110.48K

+4.37%

Jun 30, 2025

The Vanguard Group, Inc.

2.56M

5.09%

+23.77K

+0.94%

Jun 30, 2025

Novo Holdings A/S

1.50M

2.99%

+55.00

+0.00%

Jun 30, 2025

Citadel Advisors LLC

1.41M

2.8%

-39.64K

-2.74%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.38M

2.75%

-2.14K

-0.16%

Jun 30, 2025

State Street Investment Management (US)

1.38M

2.74%

-118.94K

-7.96%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Innovator IBD 50 Fund ETF

2.66%

Virtus LifeSci Biotech Products ETF

2.49%

ALPS Medical Breakthroughs ETF

2.17%

Invesco Dorsey Wright Healthcare Momentum ETF

1.66%

Tema Heart & Health ETF

1.32%

First Trust Innovation Leaders ETF

1.17%

Federated Hermes MDT Small Cap Core ETF

1.13%

First Trust Small Cap Growth AlphaDEX Fund

0.8%

SPDR S&P Biotech ETF

0.62%

First Trust NASDAQ Pharmaceuticals ETF

0.5%

Innovator IBD 50 Fund ETF

占比2.66%

Virtus LifeSci Biotech Products ETF

占比2.49%

ALPS Medical Breakthroughs ETF

占比2.17%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.66%

Tema Heart & Health ETF

占比1.32%

First Trust Innovation Leaders ETF

占比1.17%

Federated Hermes MDT Small Cap Core ETF

占比1.13%

First Trust Small Cap Growth AlphaDEX Fund

占比0.8%

SPDR S&P Biotech ETF

占比0.62%

First Trust NASDAQ Pharmaceuticals ETF

占比0.5%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据